Cardiovascular

PCSK9 inhibitors for refractory hyperlipidemia

Clinical Overview and When to Suspect Refractory Hyperlipidemia

— Maximally tolerated high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg)

— Plus ezetimibe 10 mg in most very-high-risk patients

— Documented adherence and lifestyle optimization

— ASCVD secondary prevention (very high-risk): prior MI, stroke, PAD, or multiple major events/high-risk features with LDL-C ≥70 mg/dL or non-HDL ≥100 mg/dL on max statin + ezetimibe

— Primary prevention in heterozygous familial hypercholesterolemia (HeFH): LDL-C ≥100 mg/dL on max statin + ezetimibe

— FOURIER (evolocumab): 15% relative MACE reduction

— ODYSSEY OUTCOMES (alirocumab): 15% MACE reduction post-ACS, all-cause mortality benefit

PCSK9 inhibitors (evolocumab, alirocumab) are monoclonal antibodies that bind proprotein convertase subtilisin/kexin type 9, preventing LDL-receptor degradation and lowering LDL-C by 50–60% on top of statin therapy.

Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 mRNA, dosed Q6 months after loading — same target, different mechanism.

Suspect refractory hyperlipidemia when LDL-C remains above goal despite:

Two core eligible populations per AHA/ACC 2022 expert consensus:

Homozygous FH (HoFH): evolocumab approved as adjunct; effect blunted because residual LDL-receptor function is required.

Statin intolerance alone is not an automatic indication — must first document failure of at least 2 statins (one at lowest dose), trial rosuvastatin every-other-day, and add ezetimibe/bempedoic acid before PCSK9i in most payers.

Outcomes data:

Board pearl: PCSK9 inhibitors do not lower mortality in primary prevention trials — reserve for established ASCVD or genetic dyslipidemia. The Step 3 vignette almost always involves a post-MI patient with LDL still 90–110 on atorvastatin 80 + ezetimibe.

Presentation Patterns and Key History

— 58-year-old man 6 months post-NSTEMI with PCI/DES

— On atorvastatin 80 mg, aspirin, ticagrelor, metoprolol, lisinopril

— Lipid panel at follow-up: LDL-C 102 mg/dL, non-HDL 130, TG 160

— Adherent, exercises, Mediterranean diet — "what is the next step?"

— First-degree relative with premature CAD (men <55, women <65)

— Untreated LDL >190 mg/dL in adult or >160 in child

— Tendon xanthomas, corneal arcus before age 45

— Dutch Lipid Clinic Network score ≥6 supports definite/probable FH

— Statin adherence: pill counts, pharmacy refill data, ask about social media-driven statin discontinuation

— Statin-associated muscle symptoms (SAMS): characterize as bilateral proximal, onset within weeks, resolution with washout; rule out hypothyroidism, vitamin D deficiency

— Secondary causes: hypothyroidism (check TSH), nephrotic syndrome (UA, albumin), cholestasis, uncontrolled DM, alcohol, anabolic steroids

— Dietary patterns and weight trajectory

— Lp(a) measurement — once in lifetime; elevated Lp(a) >50 mg/dL strengthens case for aggressive LDL lowering

— Document prior statin trials with specific drug, dose, duration, and reason for discontinuation

— Many payers require ezetimibe trial of ≥3 months

— Bempedoic acid increasingly required before PCSK9i approval

Classic Step 3 vignette setup:

Family history red flags suggesting FH:

History elements to extract before escalating to PCSK9i:

Insurance/access history matters at Step 3:

Key distinction: A patient with "statin intolerance" who has only tried atorvastatin 80 once is not refractory — Step 3 expects you to rechallenge with low-dose rosuvastatin or pravastatin, add ezetimibe, then bempedoic acid before reaching for a PCSK9 inhibitor. The vignette tests whether you sequence therapy correctly rather than jumping to the expensive option.

Physical Exam Findings and Vascular Assessment

— Tendon xanthomas on Achilles or extensor tendons of hands — pathognomonic for HeFH/HoFH

— Tuberous xanthomas at elbows/knees in HoFH or dysbetalipoproteinemia

— Xanthelasma (yellow periorbital plaques) — present in ~50% of FH but also seen with normal lipids

— Corneal arcus before age 45 — strongly suggests FH; after 60 is age-related

— Eruptive xanthomas on buttocks/extensor surfaces — severe hypertriglyceridemia (TG >1000), not a PCSK9i target

— Carotid bruits — suggest atherosclerotic burden; lowers threshold for aggressive LDL lowering

— Diminished pedal pulses, femoral bruits, ABI <0.9 — PAD qualifies as ASCVD

— S4 gallop, displaced PMI — signs of prior MI/LV remodeling

— Aortic stenosis murmur — calcific AS associated with elevated Lp(a)

— Ankle-brachial index in any smoker, diabetic, or symptomatic patient — identifies subclinical PAD

— Carotid intima-media thickness or CAC score can reclassify borderline primary-prevention patients but is not used to qualify for PCSK9i

— Weight, BMI, waist circumference (metabolic syndrome workup)

— Blood pressure — uncontrolled HTN amplifies residual risk

— Skin/injection-site exam for any prior subcutaneous biologic reactions

General inspection clues to genetic dyslipidemia:

Cardiovascular exam in the refractory patient:

Targeted vascular assessment:

Document baseline before initiation:

CCS pearl: On the CCS case, before prescribing a PCSK9 inhibitor, document a focused cardiovascular and vascular exam, order fasting lipid panel, hsCRP, Lp(a), HbA1c, TSH, LFTs, CK if symptomatic, and confirm medication reconciliation. Skipping the exam step or ordering the drug without documenting prior statin failure costs points. The CCS clock often advances 4 weeks before lipid recheck — plan that on the order screen.

Diagnostic Workup — Initial Labs and Risk Markers

— Total cholesterol, HDL-C, calculated LDL-C, triglycerides

— Non-HDL-C = TC − HDL; useful when TG >200 or LDL <70

— Apolipoprotein B — superior marker when LDL is low/discordant or in metabolic syndrome

— Friedewald equation invalid if TG >400 mg/dL

— Use Martin-Hopkins or direct LDL measurement at low LDL or high TG

— Measure once in lifetime in adults; genetically determined, minimally diet-responsive

— >50 mg/dL (or >125 nmol/L) = independent ASCVD risk factor

— PCSK9 inhibitors lower Lp(a) by ~25% — bonus benefit; statins do not

— TSH — hypothyroidism elevates LDL

— HbA1c, fasting glucose

— Comprehensive metabolic panel — Cr for CKD, AST/ALT for hepatic steatosis

— Urinalysis — nephrotic-range proteinuria

— CK if myalgias present (not routine baseline)

— hsCRP — residual inflammatory risk; >2 mg/L flags consideration of colchicine 0.5 mg or icosapent ethyl in select patients

— Does not gate PCSK9i but informs the broader plan

— Consider when Dutch Lipid Clinic score ≥6 or LDL ≥190 with family history

— LDLR, APOB, PCSK9 gain-of-function mutations

— Cascade screening of first-degree relatives is cost-effective and guideline-endorsed

Fasting lipid panel (12-hour fast preferred but non-fasting acceptable per 2018 guideline if TG <400):

LDL-C calculation pitfalls:

Lipoprotein(a):

Secondary cause screen before labeling "refractory":

Inflammatory and residual risk markers:

Genetic testing for FH:

Board pearl: A patient with LDL 165, TG 180, and recurrent MIs despite high-intensity statin almost certainly has elevated Lp(a) or undiagnosed HeFH. Ordering Lp(a) once and a genetic panel changes management — and qualifies cascade screening of children, a favorite Step 3 transition-of-care twist.

Diagnostic Workup — Confirming ASCVD Status and Eligibility

— Prior MI, stable/unstable angina, coronary revascularization (PCI or CABG)

— Prior ischemic stroke or TIA of atherosclerotic origin

— Symptomatic PAD: claudication with ABI <0.9, prior revascularization, or amputation

— Aortic aneurysm of atherosclerotic origin

— Multiple major ASCVD events, OR

— One major event + ≥2 high-risk conditions

— Major events: recent ACS (<12 mo), MI other than recent, ischemic stroke, symptomatic PAD

— High-risk conditions: age ≥65, HeFH, prior CABG/PCI, DM, HTN, CKD (eGFR 15–59), smoking, persistently elevated LDL ≥100 despite max therapy, HF

— Coronary artery calcium (CAC) score — CAC >100 or ≥75th percentile favors statin intensification; CAC = 0 may justify deferral except in FH, DM, smokers

— Carotid duplex, CT angiography for symptomatic patients

— Dutch Lipid Clinic Network criteria combine LDL level, family history, exam findings, genetic testing

— Score ≥8 = definite FH, 6–8 probable, 3–5 possible

— Documented ASCVD or HeFH/HoFH

— LDL above threshold on max tolerated statin + ezetimibe ≥4–12 weeks

— Adherence verified

— Pregnancy status discussed in reproductive-age women

— Insurance prior authorization with specific drug names, doses, dates, intolerance details

Confirm clinical ASCVD (required for most PCSK9i secondary-prevention indications):

"Very high-risk" ASCVD (2018 AHA/ACC) — meets criteria with either:

Imaging adjuncts (clarify primary-prevention borderline cases, not for PCSK9i approval):

FH workup confirmation:

Pre-initiation checklist before PCSK9i:

Step 3 management: When the vignette gives you a post-stroke diabetic with LDL 88 on rosuvastatin 40 + ezetimibe, recognize this is "very high-risk ASCVD" with LDL above the 70 mg/dL threshold — the correct next step is adding evolocumab or alirocumab, not increasing statin (already maxed) and not adding fibrate.

Risk Stratification and Treatment Algorithm Logic

— Step 1: High-intensity statin (atorvastatin 40–80, rosuvastatin 20–40)

— Step 2: Add ezetimibe 10 mg if LDL above threshold after 4–12 weeks

— Step 3: Add PCSK9 monoclonal antibody (evolocumab or alirocumab) OR bempedoic acid OR inclisiran

— Step 4: Combine PCSK9i with bempedoic acid in extreme refractory cases

— Very high-risk ASCVD: LDL ≥70 or non-HDL ≥100

— Stable ASCVD (not very high-risk): LDL ≥70 (consider) or ≥100 (recommend)

— HeFH primary prevention: LDL ≥100 on max therapy

— HoFH: essentially always indicated

— Evolocumab 140 mg SQ Q2W or 420 mg Q monthly — same dose for ASCVD and HeFH/HoFH

— Alirocumab 75 mg SQ Q2W, titrate to 150 mg if LDL goal not met

— Inclisiran 284 mg SQ at day 0, month 3, then Q6 months — adherence advantage; office-administered, billed under medical benefit

— Bempedoic acid PO daily — preferred when patient declines injections or has statin intolerance; smaller LDL reduction (~17–25%)

— Evolocumab/alirocumab: ~60% additional LDL drop on top of statin

— Inclisiran: ~50% reduction

— Combine PCSK9i + max statin + ezetimibe → LDL often <40 mg/dL

Sequence of LDL-lowering therapy (2022 ACC expert consensus pathway):

LDL-C thresholds prompting PCSK9i consideration:

Choosing between agents:

Expected LDL reduction:

No lower LDL limit: FOURIER/ODYSSEY showed continued benefit and safety even at LDL <25 mg/dL; do not stop or down-titrate based on "LDL too low."

Board pearl: The Step 3 algorithm answer is almost always "add ezetimibe first, then PCSK9 inhibitor" — skipping ezetimibe is the classic distractor. Conversely, in a clearly very-high-risk patient already on statin + ezetimibe with LDL >70, do not add a fibrate or niacin (no outcome benefit) — go directly to PCSK9i.

Pharmacotherapy — PCSK9 Inhibitor Regimens and Adjuncts

— 140 mg SQ every 2 weeks OR 420 mg SQ monthly (three 140 mg injections within 30 min)

— Sites: thigh, abdomen, upper arm; rotate

— Store refrigerated; warm to room temp 30 min before injection

— Approved: ASCVD, HeFH (≥10 yo), HoFH (≥10 yo), primary hyperlipidemia in adults

— 75 mg SQ Q2W, titrate to 150 mg SQ Q2W if LDL goal not met after 4–8 weeks

— Alternative 300 mg SQ monthly option

— Approved: ASCVD, HeFH; ODYSSEY OUTCOMES showed mortality benefit post-ACS

— 284 mg SQ at 0, 3 months, then every 6 months by clinician

— Mechanism: GalNAc-conjugated siRNA → hepatic uptake → degrades PCSK9 mRNA

— Advantage: 2 injections/year improves adherence

— Outcome data pending (ORION-4); approved based on LDL surrogate

— Ezetimibe 10 mg daily — must precede PCSK9i; ~20% LDL reduction; IMPROVE-IT showed event reduction

— Bempedoic acid 180 mg daily — ATP-citrate lyase inhibitor; ~17% LDL drop; CLEAR Outcomes showed MACE benefit in statin-intolerant patients; avoid with simvastatin >20 or pravastatin >40 (increased statin levels); raises uric acid → gout risk

— Icosapent ethyl 2 g BID — for residual TG 150–500 on statin in ASCVD/diabetes (REDUCE-IT)

— Fibrates (no LDL benefit; reserve for TG >500 pancreatitis prevention)

— Niacin (AIM-HIGH/HPS2-THRIVE: no benefit, more harm)

— Red yeast rice (unregulated; functionally a low-dose lovastatin)

Evolocumab (Repatha):

Alirocumab (Praluent):

Inclisiran (Leqvio):

Companion oral non-statin agents:

Drugs NOT to add for residual LDL refractoriness:

Step 3 management: In a post-ACS patient at discharge, start high-intensity statin immediately, add ezetimibe at 4-week visit if LDL ≥70, and add PCSK9 inhibitor at 8–12 week visit if still ≥70. Document the sequence — this is the pattern test-writers reward.

Pharmacology Deep Dive — Mechanism, PK, and Practical Use

— Hepatocyte LDL receptors normally bind LDL, internalize it, then recycle to surface

— PCSK9 binds the LDL-receptor, marking it for lysosomal degradation instead of recycling

— Loss-of-function PCSK9 mutations → very low LDL, low CAD risk (the genetic experiment that birthed the drug class)

— Gain-of-function mutations → autosomal dominant hypercholesterolemia

— Fully human IgG that binds circulating PCSK9 → blocks PCSK9–LDLR interaction → more receptors recycle → LDL clearance ↑

— Half-life ~11–20 days; steady state in 12 weeks

— Cleared by reticuloendothelial proteolysis — no hepatic or renal dose adjustment

— GalNAc moiety targets hepatocyte asialoglycoprotein receptor

— Loaded into RISC complex → cleaves PCSK9 mRNA → reduced PCSK9 synthesis

— Effect lasts months; steady LDL reduction ~50% with Q6-month dosing

— LDL falls within 2 weeks, nadir at 4 weeks

— Check fasting lipid panel 4–8 weeks after initiation, then every 3–12 months

— Injection-site reactions (most common: erythema, pain, bruising; <10%)

— Nasopharyngitis, URI symptoms

— Rare hypersensitivity, angioedema

— Neurocognitive complaints reported but EBBINGHAUS substudy showed no objective decline

— No increase in new-onset diabetes, hemorrhagic stroke, or cataracts

— Refrigerate 2–8°C; can be at room temp up to 30 days

— Patient must be trained on SQ self-injection; pre-filled pen vs syringe options

PCSK9 biology:

Monoclonal antibodies (evolocumab, alirocumab):

Inclisiran (siRNA):

Onset and durability:

Adverse effects:

Drug interactions: Essentially none — monoclonal antibody pharmacology bypasses CYP system. No interaction with warfarin, DOACs, antiplatelets, or statins.

Storage and handling:

Board pearl: A vignette describing a patient on warfarin, amiodarone, and atorvastatin with persistent LDL 110 — adding a PCSK9 monoclonal is safe and free of CYP interactions, unlike adding gemfibrozil (raises statin levels, risks myopathy) or doubling the statin.

Special Populations — Elderly, Renal, and Hepatic Impairment

— FOURIER and ODYSSEY OUTCOMES included patients up to 85; relative risk reduction preserved, absolute benefit often greater due to higher baseline risk

— No dose adjustment for age

— Consider life expectancy, frailty, polypharmacy, goals of care — in patients with limited prognosis (<2–3 years), the time-to-benefit (~1.5–2 years for MACE reduction) may not justify cost and injections

— Watch for injection technique challenges: arthritis, vision impairment → favor monthly evolocumab 420 mg or inclisiran Q6 months

— No dose adjustment for evolocumab, alirocumab, or inclisiran across eGFR ranges including dialysis

— Limited data in eGFR <15 or dialysis-dependent; pharmacology suggests safety

— CKD is a risk enhancer — lowers threshold for PCSK9i in primary prevention with LDL ≥100

— Statin caution: rosuvastatin max 10 mg if eGFR <30; atorvastatin preferred

— Mild–moderate (Child-Pugh A–B): no adjustment

— Severe (Child-Pugh C): no formal recommendation; data lacking, use clinical judgment

— Active liver disease or unexplained ALT >3× ULN — defer statins and reassess; PCSK9 inhibitors not hepatically metabolized but trial data excluded these patients

— PCSK9i safe in HFrEF and HFpEF; no signal for worsening HF

— Focus remains on GDMT; LDL goals same as other ASCVD

— PCSK9i does not raise HbA1c or new-onset DM risk (unlike statins which have small ~9% relative increase)

— Diabetics with ASCVD are very-high-risk → low threshold for intensification

— Cyclosporine, tacrolimus interact with statins → PCSK9 inhibitors offer a drug-interaction-free LDL-lowering option

— Discuss with transplant team; published case series supportive

Elderly patients (≥75 years):

Chronic kidney disease:

Hepatic impairment:

Heart failure:

Diabetes mellitus:

Post-transplant patients:

Key distinction: Unlike statins (avoid in active hepatitis, dose-adjust in CKD) and ezetimibe (avoid in moderate-severe hepatic impairment), PCSK9 monoclonal antibodies require no dose adjustment for kidney or liver function — making them the cleanest add-on in multi-organ disease patients.

Special Populations — Pregnancy, Pediatrics, and Reproductive Care

— PCSK9 inhibitors are not recommended in pregnancy or lactation due to lack of human data

— IgG antibodies cross the placenta in the second and third trimesters → theoretical fetal exposure

— Discontinue PCSK9i before conception (allow washout of ~3 months given long half-life)

— Statins were previously category X; FDA removed the contraindication in 2021 but they remain generally discouraged except in HoFH where benefit may outweigh risk

— Mainstay in pregnancy: diet, exercise, bile acid sequestrants (colesevelam) — not absorbed, safe

— For severe FH in pregnancy: LDL apheresis is the preferred intervention

— Discuss with reproductive-age women before initiating PCSK9i

— Document method and plan to discontinue if pregnancy planned

— Unknown if PCSK9 mAbs are excreted in milk; IgG generally minimally transferred and digested

— Manufacturer recommends avoidance; shared decision-making

— Evolocumab approved age ≥10 for HeFH and HoFH

— Alirocumab approved ≥8 years for HeFH (2024 expansion)

— Statin remains first-line in pediatric FH, typically starting age 8–10

— HoFH children: often require statin + ezetimibe + PCSK9i ± evinacumab (ANGPTL3 inhibitor) ± LDL apheresis

— Identified FH proband → screen all first-degree relatives including children ≥2 years with lipid panel

— Cost-effective and a public health intervention USMLE rewards

— Pediatric-to-adult lipid clinic handoff; reinforce adherence as autonomy increases

— Address contraception/pregnancy planning at every visit in young women with FH

Pregnancy:

Contraception counseling:

Lactation:

Pediatrics:

Cascade screening (Step 3 favorite):

Adolescent transitions of care:

Step 3 management: A 28-year-old woman with HeFH on rosuvastatin + evolocumab presents with positive pregnancy test — the correct order set is: stop both statin and PCSK9i, start colesevelam if LDL severely elevated, refer to maternal-fetal medicine and lipid specialist, plan LDL apheresis if LDL remains >300, and resume therapy after delivery/weaning.

Complications and Adverse Outcomes

— Injection-site reactions (5–10%): erythema, induration, pruritus, mild pain — rotate sites, apply ice

— Nasopharyngitis, URI, influenza-like symptoms — slightly higher than placebo

— Myalgia — similar rate to placebo; reassures patients with prior statin SAMS

— Hypersensitivity reactions — rash, urticaria; rare angioedema → discontinue

— Immunogenicity — anti-drug antibodies in <1%; rarely reduces efficacy

— Neurocognitive symptoms — case reports; EBBINGHAUS prospective cognitive study showed no decline at LDL <25

— Very low LDL-C (<25 mg/dL): no increased adverse outcomes in trials; do not down-titrate

— Hemorrhagic stroke risk — pooled analyses show no increase with PCSK9i (small statin signal not replicated)

— New-onset diabetes — not increased with PCSK9 mAbs or inclisiran

— Cataracts — no signal

— Missed doses → LDL rebounds within 4–6 weeks for mAbs

— Inclisiran's biannual dosing improves adherence but missed clinic visits delay re-dosing

— Wholesale acquisition cost ~$5,800/year (post-2018 price reduction); prior authorization burden

— Patient assistance programs through manufacturers

— Step 3 increasingly tests recognition that cost and access are clinical considerations

— Inclisiran: higher rate of mild injection-site reactions; no cardiovascular outcomes data yet

— Bempedoic acid (companion): increased uric acid → gout flares, tendon rupture (rare), small AKI signal

— If LDL drop <30% after 8 weeks of evolocumab/alirocumab → reassess adherence, injection technique, secondary causes; consider switching agent or adding bempedoic acid

Common, generally mild adverse effects:

Uncommon but clinically relevant:

Lipid-related "complications" that are NOT problems:

Adherence-related complications:

Financial toxicity:

Drug-specific:

Failure of therapy:

Board pearl: A patient on evolocumab returns with LDL 15 mg/dL — the correct response is continue therapy unchanged. There is no evidence-based lower LDL limit; counseling the patient and continuing the regimen is the Step 3 answer over dose reduction or discontinuation.

When to Escalate Care — Lipid Specialist, Apheresis, and Inpatient Considerations

— HoFH — always co-manage; consider evinacumab, apheresis, liver transplant

— HeFH with LDL >190 despite statin + ezetimibe + PCSK9i

— Suspected familial chylomicronemia (TG >1000, recurrent pancreatitis) — different pathway (volanesorsen, fibrates, omega-3s)

— Recurrent ASCVD events despite max therapy

— Prior authorization denials — specialists often have streamlined approval pathways

— HoFH with LDL >300 on max therapy, or HeFH with LDL >300 (no CAD) or >200 with CAD

— Performed every 1–2 weeks; lowers LDL acutely by ~70%

— Bridge during pregnancy in severe FH

— Severe hypertriglyceridemia with acute pancreatitis — admit, IV insulin ± plasmapheresis (not a PCSK9i scenario)

— Acute coronary syndrome — initiate or continue high-intensity statin in-hospital; discuss PCSK9i initiation at discharge or within 4–8 weeks (some centers initiate in-hospital post-ACS based on ODYSSEY OUTCOMES)

— Acute ischemic stroke with known FH or recurrent events — coordinate lipid plan at discharge

— Post-MI patients should leave hospital on high-intensity statin regardless of baseline LDL

— Document LDL goal and follow-up plan at discharge

— Cardiac rehab referral reinforces lifestyle pillar

— Specialty pharmacy delivery for PCSK9 mAbs

— In-office administration model for inclisiran (medical benefit billing)

— Anticipate 2–6 week prior authorization timeline; do not let it lapse care

Outpatient referral to lipid specialist:

LDL apheresis indications (FDA-approved):

When to consider inpatient management of dyslipidemia issues:

Cardiology and stroke neurology involvement:

Pharmacy/care coordination:

CCS pearl: On the CCS case of a post-NSTEMI patient at 6-week follow-up with LDL 95 on atorvastatin 80, the optimal order sequence is: add ezetimibe 10 mg daily, schedule lipid recheck in 6 weeks, refer to cardiac rehab, counsel on adherence. If at the 12-week recheck LDL is still ≥70, initiate evolocumab 140 mg SQ Q2W and arrange prior authorization documentation. Premature PCSK9i initiation before ezetimibe trial is penalized.

Key Differentials — Other Causes of Refractory LDL Elevation

— HeFH: 1 in 250; LDL typically 190–400; tendon xanthomas; premature CAD by 50s

— HoFH: 1 in 250,000–1 million; LDL >400 from childhood; xanthomas before age 10; MI in teens/20s

— Familial defective ApoB-100: clinically indistinguishable from HeFH

— PCSK9 gain-of-function mutation: rare; same phenotype

— Autosomal recessive hypercholesterolemia (LDLRAP1): rare; phenotype between HeFH and HoFH

— Multiple small-effect SNPs aggregating to elevated LDL

— More common than monogenic FH in patients with LDL 190–250

— Same treatment approach

— Autosomal recessive defect in ABCG5/ABCG8 → plant sterol absorption

— Mimics FH with xanthomas in childhood

— Ezetimibe is uniquely effective; statins less so; bile acid sequestrants helpful

— PCSK9i has limited role

— ApoE2/E2 genotype + metabolic stressor

— Palmar (palmar crease) and tuberoeruptive xanthomas — pathognomonic

— Both TC and TG elevated (300–500 each)

— Responds to fibrates and statins, not primarily a PCSK9i target

— Elevated LDL + TG, often with metabolic syndrome

— Treat LDL with statin/ezetimibe/PCSK9i; treat residual TG with icosapent ethyl if ASCVD

— Isolated elevated Lp(a) with otherwise normal lipids → premature ASCVD

— No approved Lp(a)-targeted therapy yet (pelacarsen, olpasiran in trials)

— PCSK9i lowers Lp(a) ~25% — partial benefit

Familial hypercholesterolemia variants (same category, different genetics):

Polygenic hypercholesterolemia:

Sitosterolemia:

Dysbetalipoproteinemia (type III hyperlipoproteinemia):

Combined hyperlipidemia:

Lp(a) hyperlipoproteinemia:

Board pearl: Tendon xanthomas + LDL >250 in a 35-year-old with two MI events screams HeFH → genetic testing, cascade screening, max statin + ezetimibe + PCSK9 inhibitor. Palmar xanthomas with combined TC/TG elevation point instead to dysbetalipoproteinemia → fibrate + statin, not PCSK9i.

Key Differentials — Secondary (Non-Genetic) Causes to Exclude

— Hypothyroidism — markedly elevates LDL via reduced LDL-receptor expression; check TSH at baseline and with any unexplained LDL rise; correct with levothyroxine, recheck lipids in 6–8 weeks

— Nephrotic syndrome — urinary albumin loss drives hepatic lipoprotein overproduction; treat underlying glomerular disease

— Cholestatic liver disease (PBC) — elevated LDL, often massively elevated cholesterol; xanthelasma common

— Chronic kidney disease — atherogenic dyslipidemia with elevated TG, low HDL, small dense LDL

— Uncontrolled diabetes mellitus — primarily TG-driven; HbA1c >9 amplifies lipids

— Obesity, metabolic syndrome — combined dyslipidemia pattern

— Alcohol use — elevates TG and HDL

— Glucocorticoids — raise LDL and TG

— Atypical antipsychotics (olanzapine, clozapine)

— Thiazide and beta-blockers — modest TG/LDL effect

— Cyclosporine, tacrolimus — post-transplant dyslipidemia

— Protease inhibitors (older HIV regimens)

— Retinoids (isotretinoin) — marked TG elevation

— Anabolic steroids, androgen deprivation therapy

— High saturated fat, trans fat intake

— Sedentary behavior

— Weight gain

— Recent significant alcohol intake before fasting panel

— Verify with pharmacy refill data; ~50% of statin patients discontinue within 1 year

— Address statin myths (memory loss, diabetes fear) with evidence

— Consider lower-dose rosuvastatin + ezetimibe combo as adherence-friendly alternative

Secondary hyperlipidemia mimics must be addressed before labeling refractory:

Medication-induced dyslipidemia:

Lifestyle confounders:

Adherence failure (the #1 "secondary cause"):

Step 3 management: Before signing off on "PCSK9 inhibitor next step," the test wants you to order TSH, urinalysis, HbA1c, CMP, and confirm adherence. A vignette mentioning fatigue, weight gain, and constipation with LDL that doubled despite statin = check TSH first — treating hypothyroidism may normalize lipids and avoid escalation entirely.

Secondary Prevention, Discharge Plan, and Long-Term Strategy

— High-intensity statin (atorvastatin 80 or rosuvastatin 40) — regardless of baseline LDL

— Aspirin 81 mg indefinitely

— P2Y12 inhibitor for 6–12 months (longer per cardiology)

— Beta-blocker if LV dysfunction or recent MI

— ACE inhibitor/ARB if HFrEF, diabetes, HTN, or CKD

— Document plan to escalate to ezetimibe ± PCSK9 inhibitor at follow-up based on LDL response

— Very high-risk ASCVD: LDL <70, with consideration of <55 per ESC and increasingly endorsed in US practice

— HeFH primary prevention: LDL <100 (or ≥50% reduction)

— Aggressive lowering (LDL <40) is acceptable and supported by trial data

— Blood pressure <130/80

— HbA1c individualized; ASCVD patients with DM consider SGLT2 inhibitor or GLP-1 agonist for CV benefit

— Smoking cessation — counseling + varenicline/NRT

— Mediterranean or DASH diet; weight loss 5–10%

— Exercise 150 min/wk moderate-intensity

— Cardiac rehabilitation referral after ACS, PCI, CABG, stable angina, HF

— Icosapent ethyl 2 g BID if TG 150–500 in ASCVD/DM (REDUCE-IT)

— Colchicine 0.5 mg daily for recurrent ASCVD with hsCRP elevation (LoDoCo2, FDA approved 2023)

— Bempedoic acid for statin-intolerant or as add-on

— Therapy is lifelong in ASCVD and FH

— Reassess annually for adherence, side effects, evolving evidence

— Inclisiran offers Q6 month dosing; transitioning a stable mAb patient to inclisiran is reasonable for adherence

Discharge medication bundle post-ACS or revascularization:

LDL targets (2018/2022 AHA-ACC):

Non-LDL secondary prevention pillars:

Adjunct pharmacotherapy in residual risk:

Long-term PCSK9i continuation:

Board pearl: A patient discharged after PCI with LDL 140 on no prior therapy should leave on atorvastatin 80 mg + ASA + ticagrelor + beta-blocker + ACE-I, with lipid recheck at 4–8 weeks, ezetimibe added if LDL ≥70, and PCSK9 inhibitor by month 3 if still above goal. The Step 3 trap is delaying intensification — be aggressive on the timeline.

Follow-Up, Monitoring Parameters, and Counseling

— Baseline before therapy start

— 4–8 weeks after each medication change (statin start/intensify, ezetimibe add, PCSK9i start)

— Every 3–12 months once stable on regimen

— Annually for stable long-term patients on PCSK9i

— ALT/AST baseline before statin; repeat only if symptoms (jaundice, fatigue, RUQ pain)

— CK only if muscle symptoms — routine monitoring not recommended

— HbA1c annually given small statin-related DM risk

— No specific safety labs required for PCSK9 inhibitors beyond lipid response

— Pharmacy refill data (proportion of days covered)

— Patient self-report with non-judgmental questioning

— Ask about injection technique, refrigeration, missed doses

— Inclisiran clinic visit attendance

— Reinforce that lipid therapy is lifelong, including during periods of "normal" labs

— Address statin/PCSK9i myths — neurocognitive concerns, "LDL too low"

— Lifestyle reinforcement: diet, exercise, weight, tobacco

— Symptom inquiry: muscle pain, new-onset diabetes symptoms, injection reactions

— Vaccination status: influenza, pneumococcal, COVID-19, RSV — ASCVD patients are higher risk

— Refer after MI, PCI, CABG, stable angina, HF, valve surgery, heart transplant

— Improves mortality and adherence to lipid therapy

— Often underutilized — a Step 3 quality-improvement target

— Document LDL goal in problem list

— Share lipid plan with PCP, cardiology, endocrinology

— Use patient portal messaging for LDL results and counseling

Lipid panel monitoring schedule:

Safety labs:

Adherence verification:

Counseling content at each visit:

Cardiac rehabilitation:

Coordination of care:

Reproductive counseling at every visit for women of childbearing potential on PCSK9i

CCS pearl: On a CCS lipid follow-up case, ordering "fasting lipid panel" at the 6-week interval, advancing the clock, reviewing results, then intensifying therapy earns points. Forgetting the recheck and instead seeing the patient at 6 months without lab data is a classic timing error — order labs to coincide with each visit.

Ethical, Legal, and Patient Safety Considerations

— PCSK9 inhibitors cost ~$5,800/year; insurance prior authorization is a documented barrier to therapy for eligible patients

— Physicians have an ethical duty to advocate for access — provide detailed letters of medical necessity, document prior therapy failures, and use manufacturer patient assistance

— Step 3 increasingly tests recognition that deferring an indicated therapy purely on cost without exploring options is suboptimal

— Discuss expected LDL reduction, MACE benefit (~1.5% absolute over 2–3 years), risks (injection reactions, unknown long-term pregnancy risk), cost, injection burden, and alternatives (bempedoic acid, inclisiran)

— Document the conversation

— Respect patient values — some prefer oral therapy or refuse injections; bempedoic acid is a reasonable alternative with outcome data

— Hospital discharge: failure to communicate lipid plan to PCP results in dropped intensification — use discharge summary template with LDL goal and follow-up plan

— Pediatric-to-adult transition for FH patients: ensure handoff to adult lipidologist; reproductive counseling for adolescent women

— Pregnancy transition: active medication reconciliation when patient becomes pregnant; stop PCSK9i and statin, communicate with OB

— Cascade screening in newly diagnosed FH: counsel patient about screening first-degree relatives, including children ≥2 years — not legally mandated but an ethical and clinical standard

— Genetic counseling referral before broad family genetic testing

— Injection safety: teach proper SQ technique, sharps disposal, allergy recognition

— Polypharmacy reconciliation at each visit — PCSK9i is drug-interaction-free but the patient's other meds are not

— Avoid duplicative therapy — confirm patient is not on two PCSK9-targeting agents

— Specific statin names, doses, dates, reason for discontinuation

— LDL values at each step

— ASCVD diagnosis with ICD-10 specificity

Cost and access equity:

Informed consent and shared decision-making:

Transition-of-care risks (Step 3 favorite):

Mandatory considerations:

Patient safety:

Documentation for prior authorization (medicolegal protection):

Board pearl: A vignette describing a post-MI patient discharged on atorvastatin 80 who returns 3 months later having stopped the statin because of "muscle aches" his cousin told him about — the Step 3 answer is non-judgmental discussion, statin rechallenge at lower dose, ezetimibe add-on, and PCSK9i if persistently above goal, not immediate jump to PCSK9 inhibitor or acceptance of discontinuation.

High-Yield Associations and Rapid-Fire Clinical Facts

— Evolocumab/alirocumab → monoclonal antibodies vs circulating PCSK9

— Inclisiran → siRNA silencing hepatic PCSK9 mRNA

— Both restore LDL-receptor recycling

— Evolocumab: 140 mg Q2W or 420 mg monthly SQ

— Alirocumab: 75–150 mg Q2W SQ

— Inclisiran: 284 mg SQ at 0, 3, then Q6 months

— LDL ↓ 50–60% on top of statin

— Lp(a) ↓ ~25% (only PCSK9i class achieves this)

— Apo B ↓ proportionally

— TG modestly reduced

— HDL slightly increased

— FOURIER — evolocumab, stable ASCVD, 15% MACE reduction, no mortality benefit

— ODYSSEY OUTCOMES — alirocumab, post-ACS, 15% MACE reduction, all-cause mortality benefit

— EBBINGHAUS — no neurocognitive harm

— ORION — inclisiran LDL surrogate; outcomes trial pending

— ASCVD with LDL ≥70 on max statin + ezetimibe

— HeFH with LDL ≥100 on max therapy

— HoFH (evolocumab; consider evinacumab)

— Primary prevention without FH or very high risk

— Hypertriglyceridemia

— Statin-naive patients (must trial statin first)

— No new-onset DM

— No hemorrhagic stroke increase

— No cognitive decline

— No transaminase elevation

— Tendon xanthomas → HeFH

— Tuberous xanthomas + early childhood MI → HoFH

— Palmar xanthomas → dysbetalipoproteinemia (not a PCSK9i scenario)

— Eruptive xanthomas → severe hypertriglyceridemia (not a PCSK9i scenario)

— Elevated Lp(a) + premature CAD → PCSK9i provides bonus Lp(a) reduction

Mechanism rapid recall:

Dosing snapshots:

Expected effects:

Outcomes trials:

Indications cheatsheet:

NOT indicated:

Adverse effect "no signals":

Key associations:

Drug interaction recall: None clinically significant — major advantage in polypharmacy patients (post-transplant, HIV, complex CV regimens).

Cost recall: ~$5,800/year wholesale; check formulary; document prior step therapy.

Board pearl: When a Step 3 stem describes a patient on cyclosporine post-renal transplant with persistent LDL elevation, the PCSK9 inhibitor is the answer — no CYP interaction, no renal dose adjustment, no transplant rejection signal. Doubling the statin risks rhabdomyolysis.

Board Question Stem Patterns

— 6 months post-MI, on atorvastatin 80, LDL 95

— Wrong answers: Increase atorvastatin (already max), add fenofibrate, add niacin, stop statin

— Right answer: Add ezetimibe 10 mg; if LDL still ≥70 at next recheck → PCSK9 inhibitor

— Two MIs despite atorvastatin 80 + ezetimibe, LDL 78

— Right answer: Add evolocumab or alirocumab (very-high-risk ASCVD with multiple events)

— 30-year-old with tendon xanthomas, LDL 280, father died of MI at 45

— Right next steps: Genetic testing/Dutch criteria, cascade screening of first-degree relatives, high-intensity statin, ezetimibe, PCSK9 inhibitor

— Myalgia on atorvastatin and simvastatin

— Right sequence: Rechallenge with low-dose rosuvastatin every other day, add ezetimibe, then bempedoic acid, then PCSK9i — not jumping to PCSK9i first

— LDL doubled despite stable statin; complaints of fatigue, weight gain

— Right answer: Check TSH before escalating — treat hypothyroidism

— Newly pregnant patient on evolocumab + rosuvastatin

— Right answer: Discontinue both, consider colesevelam, refer MFM + lipidologist, apheresis if severe FH

— Renal transplant on cyclosporine, LDL 160 on atorvastatin 20 (can't increase due to interaction)

— Right answer: Add PCSK9 inhibitor — no CYP interaction

— Recurrent MI with normal LDL but Lp(a) 120 nmol/L

— Right answer: Optimize LDL aggressively with PCSK9 inhibitor (lowers Lp(a) ~25%); no Lp(a)-specific drug currently FDA-approved

— Patient stopped statin due to social media concerns

— Right answer: Empathetic counseling, rechallenge, reinforce evidence — not immediate PCSK9i

— Patient on PCSK9i with LDL 18

— Right answer: Continue therapy unchanged — no harm at low LDL

Pattern 1 — Post-ACS refractory LDL:

Pattern 2 — Recurrent events on max therapy:

Pattern 3 — FH proband:

Pattern 4 — Statin intolerance:

Pattern 5 — Secondary cause masquerade:

Pattern 6 — Pregnancy on PCSK9i:

Pattern 7 — Post-transplant lipid management:

Pattern 8 — Elevated Lp(a):

Pattern 9 — Adherence and cost (Step 3 specific):

Pattern 10 — LDL "too low":

Step 3 management: The unifying decision rule: statin → ezetimibe → PCSK9 inhibitor, with secondary-cause workup and adherence verification at every step. Memorize the sequence; the test rewards correct ordering more than any single drug choice.

One-Line Recap

PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) are add-on LDL-lowering agents that reduce LDL-C by 50–60% and lower MACE in patients with established ASCVD or familial hypercholesterolemia whose LDL remains above goal despite maximally tolerated statin plus ezetimibe.

Eligibility recap: Very-high-risk ASCVD with LDL ≥70, or HeFH with LDL ≥100, on max statin + ezetimibe — confirm secondary causes (TSH, UA, HbA1c) are excluded and adherence verified.

Sequence recap: High-intensity statin → ezetimibe → PCSK9 inhibitor (or bempedoic acid if statin-intolerant) → consider inclisiran for adherence; reserve apheresis and evinacumab for HoFH.

Safety recap: No CYP interactions, no renal/hepatic dose adjustment, no diabetes or cognitive signal, no LDL "too low" — discontinue in pregnancy (stop before conception), counsel on injection technique, monitor lipids 4–8 weeks after each change then every 3–12 months.

Step 3 recap: Expect vignettes testing correct sequencing, transition-of-care timing post-ACS, cascade screening in FH, post-transplant lipid management, and recognition that elevated Lp(a) is partially addressed by PCSK9i — always document prior statin trial details for prior authorization, refer to cardiac rehab, and reinforce that lipid therapy is lifelong.

Board pearl: When in doubt on Step 3, add ezetimibe before reaching for the PCSK9 inhibitor, check TSH and adherence before labeling refractory, and never stop or reduce PCSK9i for a "low" LDL — these three reflexes capture the majority of testable management decisions in this topic.